BofA raises target for Gilead Sciences stock to USD 164.00
Published on 10/13/2026 at 16:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and price position
- On October 12, 2026, BofA lifted its Gilead target from USD 162.00 to USD 164.00.
- Revenue was USD 7.80 billion in the second quarter of 2026 versus USD 7.40 billion consensus.
- Gilead Sciences stock costs EUR 132.62 at Lang & Schwarz on October 13, 2026 at 4:06 p.m. CEST, minus 1.40 percent versus the Xetra close of October 12, 2026.
- Gilead had a negative P/E of 55.69 and a USD 185.0 billion market capitalization on October 13, 2026.
Gilead Sciences (ISIN US3755581036) is facing a higher analyst target after BofA Securities lifted its objective from USD 162.00 to USD 164.00 on October 12, 2026. Against Gilead's Nasdaq price of USD 149.17 at 10:14 a.m. ET on October 13, 2026, the new target lies 9.94 percent above the price, based on the current USD quote. Gilead Sciences was trading at EUR 132.62 at Lang & Schwarz on October 13, 2026 at 4:06 p.m. CEST, down 1.40 percent versus the Xetra close of October 12, 2026 at EUR 134.50.
Revenue exceeded consensus
Gilead's second-quarter 2026 revenue reached USD 7.80 billion, compared with USD 7.40 billion consensus. Markets Insider reported on October 7, 2026 that the quarter ending June 30, 2026 also included a GAAP net loss of USD 10.50 billion, compared with a prior-year net profit of USD 1.96 billion.
The revenue comparison gives the analyst target a more specific operating backdrop. BofA's third-quarter model put Biktarvy sales at USD 3.922 billion versus USD 3.908 billion consensus, according to Investing.com on October 12, 2026.
Price stays below yearly high
On Nasdaq, Gilead's USD 149.17 quote stood inside a 52-week range of USD 114.02 to USD 157.29 on October 13, 2026. The price was 5.16 percent below the yearly high, while the same-day volume was 405,979 shares against an average of 5,994,223 shares.
Valuation and reporting figures
Gilead's market capitalization was USD 185.0 billion and its negative P/E was 55.69 on October 13, 2026. The company operates in healthcare and drug manufacturing, with medicines across virology, oncology and inflammation.
Comparison with peers
Gilead Sciences: minus 1.40 percent, P/E minus 55.69, market capitalization USD 185.0 billion.
Amgen (NASDAQ, USD): minus 0.39 percent, P/E 25.81, market capitalization USD 224.5 billion.
Vertex Pharmaceuticals (NASDAQ, USD): minus 2.20 percent, P/E 28.88, market capitalization USD 125.8 billion.
Lang & Schwarz afternoon quote
The euro quote placed Gilead at EUR 132.62 at Lang & Schwarz on October 13, 2026 at 4:06 p.m. CEST, down 1.40 percent against the Xetra close of October 12, 2026 at EUR 134.50. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences market data
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 13, 2026, 4:06 p.m. CEST): EUR 132.62
- Change versus Xetra close: minus 1.40 percent
- Xetra close (October 12, 2026): EUR 134.50
- Market capitalization: USD 185.0 billion (as of October 13, 2026)
- 52-week range: USD 114.02-157.29 (as of October 13, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Market context: Market report S&P 500.
